Azzouzi AR et al., 2016-12-20: Phase 3 randomised trial of padeliporfin (WST11) vascular-targeted photodynamic therapy versus active surveillance in 413 men with LOW-risk localised prostate cancer: 49% had a negative biopsy at 24 months versus 14% on surveillance – the study behind the '49% prostate remission' figure the docu-series coverage uses, and it used padeliporfin, not methylene blue.
101 (49%) men in the vascular-targeted photodynamic therapy group had a negative prostate biopsy result at 24 months post treatment compared with 28 (14%) men in the active surveillance group (adjusted risk ratio 3·67, 95% CI 2·53-5·33; p<0·0001)
Azzouzi AR et al., 2016-12-20: Phase 3 randomised trial of padeliporfin (WST11) vascular-targeted photodynamic therapy versus active surveillance in 413 men with LOW-risk localised prostate cancer: 49% had a negative biopsy at 24 months versus 14% on surveillance – the study behind the '49% prostate remission' figure the docu-series coverage uses, and it used padeliporfin, not methylene blue. C9/F2/F3 Azzouzi 2017 (PCM301). Study type: open-label phase 3 randomised controlled trial, N=413 (206 vs 207), 47 European centres. Country: multi-country Europe. Dose: padeliporfin 4 mg/kg IV over 10 min, optical fibres in the prostate, 753 nm laser at 150 mW/cm for 22 min 15 s. Funder: Steba Biotech (the drug's maker). Conflicts: not stated in the PubMed record. Comparator: active surveillance. Key distinctions from the source's framing: the population is LOW-risk Gleason 3 disease, not late-stage cancer; the photosensitizer is padeliporfin (a palladium-bacteriopheophorbide), not methylene blue; and the endpoint is a negative biopsy, not remission after other options were exhausted. Also filed as MTN-11 (claims C3, C9). Study type: randomized trial.
